Stephanie Verstraete - Teladoc Chief Marketing Officer
| TDOC Stock | USD 6.97 0.03 0.43% |
Executive
Ms. Stephanie Verstraete is Chief Marketing Officer in January 2016. Prior to joining Teladoc Health, Ms. Verstraete served as Chief Marketing Officer of Truveris, a healthcare technology company focused cloudbased data analytics solutions, beginning in 2014. From 2011 to 2014, Ms. Verstraete served as Chief Marketing Officer of Room Key Inc. Ms. Verstraete is responsible for the market positioning of Teladoc Health brand and growing the product portfolio. Prior to joining Teladoc Health, Ms. Verstraete also held marketing leadership roles at highprofile brands including Match.com, Expedia, Kraft and Frito Lay since 2016.
| Age | 51 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 2 Manhattanville Road, Purchase, NY, United States, 10577 |
| Phone | 203 635 2002 |
| Web | https://www.teladochealth.com |
Teladoc Management Efficiency
The company has return on total asset (ROA) of (0.0357) % which means that it has lost $0.0357 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1418) %, meaning that it created substantial loss on money invested by shareholders. Teladoc's management efficiency ratios could be used to measure how well Teladoc manages its routine affairs as well as how well it operates its assets and liabilities. As of August 5, 2025, Return On Tangible Assets is expected to decline to -0.58. The current year's Return On Capital Employed is expected to grow to -0.38. At present, Teladoc's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 58.6 M, whereas Non Current Assets Total are forecasted to decline to about 1.8 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bruno Miranda | Doximity | N/A | |
| Vivian Welsh | Veeva Systems Class | N/A | |
| Richie Jain | Schrodinger | 41 | |
| Anna Nesterova | American Well Corp | N/A | |
| Brendan OGrady | American Well Corp | 53 | |
| Paul McNeice | American Well Corp | 48 | |
| Mike Beachy | Schrodinger | N/A | |
| Jason Medeiros | American Well Corp | 46 | |
| Rana Strellis | GE HealthCare Technologies | N/A | |
| Jahid Khandaker | GE HealthCare Technologies | N/A | |
| George Newcomb | GE HealthCare Technologies | 58 | |
| Ben Greenberg | Doximity | N/A | |
| Yvonne Esq | Schrodinger | 54 | |
| Mark CPA | American Well Corp | 60 | |
| Nathalie Lacoste | Schrodinger | N/A | |
| Bradford JD | American Well Corp | 48 | |
| Shane Brauner | Schrodinger | 47 | |
| Kathy Weiler | American Well Corp | 55 | |
| Carolynne Borders | GE HealthCare Technologies | N/A | |
| Craig Overpeck | Doximity | N/A | |
| Duncan Wright | Schrodinger | N/A | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0357 |
Teladoc Leadership Team
Elected by the shareholders, the Teladoc's board of directors comprises two types of representatives: Teladoc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teladoc. The board's role is to monitor Teladoc's management team and ensure that shareholders' interests are well served. Teladoc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teladoc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mike Waters, Chief Officer | ||
| Chris Stenrud, Chief Officer | ||
| Andrew Turitz, Senior Vice President of Corporate Development | ||
| Catherine Jacobson, Independent Director | ||
| Stella Sanchez, Chief Marketing | ||
| Michelle Bucaria, Chief Human Resource Officer | ||
| Christopher Bischoff, Independent Director | ||
| David Shedlarz, Independent Director | ||
| William Frist, Independent Director | ||
| Mark Smith, Independent Director | ||
| CPA III, CEO Director | ||
| MD EE, CoFounder | ||
| Laura Whipple, Chief Officer | ||
| Nikolaos Nanis, Chief Officer | ||
| Lewis Levy, Chief Medical Officer | ||
| Alon Matas, President BetterHelp | ||
| Kelly Bliss, President Health | ||
| Fernando Madeira, President BetterHelp | ||
| Andy Puterbaugh, President Systems | ||
| Vidya RamanTangella, Chief Officer | ||
| Gabriel Cappucci, Senior Vice President Chief Accounting Officer, Controller | ||
| Yulun Wang, Head of Research and Development | ||
| Kenneth Paulus, Independent Director | ||
| Stephanie Verstraete, Chief Marketing Officer | ||
| Hemant Taneja, Director | ||
| Glen Tullman, Director | ||
| Jason Gorevic, Chief Executive Officer, Director | ||
| Courtney McLeod, Director Communication | ||
| Peter McClennen, Independent Director | ||
| Michael Waters, Chief Officer | ||
| Sandra Fenwick, Independent Director | ||
| Joseph Cpa, Senior Officer | ||
| Mala Murthy, Chief Financial Officer | ||
| David Snow, Independent Chairman of the Board | ||
| David Sides, Chief Operating Officer | ||
| Richard Napolitano, Senior Vice President Chief Accounting Officer | ||
| Thomas McKinley, Independent Director | ||
| Karen Daniel, Independent Director | ||
| Claus Jensen, Chief Officer | ||
| Daniel Trencher, Senior Vice President - Corporate Strategy | ||
| Adam Vandervoort, Chief Legal Officer and Secretary | ||
| Arnnon Geshuri, Chief Human Resource Officer | ||
| Adam JD, Chief Secretary | ||
| Stephany Verstraete, Chief Officer | ||
| Laizer Kornwasser, President Markets | ||
| Michael Minchak, Vice Relations | ||
| George Brooks, CoFounder | ||
| Jamila Taylor, Chief Officer | ||
| CPA CFA, Vice Relations | ||
| Carlos Nueno, President International |
Teladoc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teladoc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0357 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 1.58 B | ||||
| Shares Outstanding | 176.69 M | ||||
| Shares Owned By Insiders | 0.97 % | ||||
| Shares Owned By Institutions | 74.60 % | ||||
| Number Of Shares Shorted | 24.66 M | ||||
| Price To Earning | (21.84) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teladoc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teladoc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teladoc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teladoc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teladoc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Teladoc Stock refer to our How to Trade Teladoc Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teladoc. If investors know Teladoc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teladoc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets | Return On Equity |
The market value of Teladoc is measured differently than its book value, which is the value of Teladoc that is recorded on the company's balance sheet. Investors also form their own opinion of Teladoc's value that differs from its market value or its book value, called intrinsic value, which is Teladoc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teladoc's market value can be influenced by many factors that don't directly affect Teladoc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teladoc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teladoc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teladoc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.